The Patient as a Driver of Change: an Intervention Study to Reduce the Use and Impact of Potentially Inappropriate Medications Among Older Adults
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Polypharmacy
- Sponsor
- Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal
- Enrollment
- 300
- Locations
- 1
- Primary Endpoint
- Complete discontinuation of the targeted potentially inappropriate medication (e.g. benzodiazepines, oxybutynin)
- Status
- Terminated
- Last Updated
- 12 years ago
Overview
Brief Summary
An educational intervention targeting community-dwelling older adults will lead to a reduction in potentially inappropriate prescriptions (e.g. benzodiazepines, oxybutynin).
Cessation of potentially inappropriate medications (e.g. benzodiazepines, oxybutynin)will lead to improved cognitive outcomes in older adults.
Detailed Description
This study tests the effectiveness of a knowledge transfer tool for empowering patients to engage in collaborative discontinuation of potentially inappropriate medication with their pharmacist and/or physician
Investigators
Cara Tannenbaum
Dr.
Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal
Eligibility Criteria
Inclusion Criteria
- •65 year old human adults
- •who fill a prescription for at least 5 medications
- •community dwelling
- •chronic use (3 months or longer) of at least one potentially inappropriate medication (e.g. benzodiazepine, oxybutynin)
Exclusion Criteria
- •patients with severe mental illness, dementia and epilepsy
- •concomitant consumption of any other antipsychotic medication (including lithium, olanzapine, clozapine, quetiapine, risperidone, haloperidol etc.)
- •concomitant consumption of any antiepileptic (including carbamazepine, valproate, gabapentin, lamotrigine, topiramate, oxcarbazepine etc.)
- •concomitant consumption of a cholinesterase inhibitor or memantine
Outcomes
Primary Outcomes
Complete discontinuation of the targeted potentially inappropriate medication (e.g. benzodiazepines, oxybutynin)
Time Frame: 6 months post-intervention
Secondary Outcomes
- Cognitive function(6-months post-intervention)
- Sleep efficiency(6-months)
- incontinence-related self-efficacy(6-months post-intervention)
- frequency of urinary incontinence episodes(6-months post-intervention)